GBIM:OTCMKTS
GlobeImmune Inc
0,00010 USD
0,00%
(0,00) 1 D.
09-29, 15:48:52 GMT−4 · USD
search
Visi simboliai
| Simbolis | Kaina | Keisti | Pokytis, % |
|---|
insights_autoGeneruojamos svarbiausios „GBIM“ įžvalgos...
Rinkos kapitalizacija
580,00
Vid. kiekis
1,74 tūkst.
Apimtis
0,00
52 sav. aukšta
0,04 USD
52 sav. žema
0,00 USD
Neapmokėtos akcijos
5,75 mln.
Darbuotojų skaičius
22
Rinkos kapitalizacija
580,00
Vid. kiekis
1,74 tūkst.
Apimtis
0,00
52 sav. aukšta
0,04 USD
52 sav. žema
0,00 USD
Neapmokėtos akcijos
5,75 mln.
Darbuotojų skaičius
22
Naujienų istorijos
Iš žiniatinklio šaltinių ir naujienų partnerių
Traders.lt
·
prieš 2 dienas
Prognozuoja didžiausią S&P500 kritimą nuo 2008 metų
Investing News Network
·
prieš 10 minučių
Oracle NetSuite Announces Launch of AI-first QuickStart: NYSE Content Update
The Arkansas Democrat-Gazette
·
prieš 17 minučių
Little Rock based BSR Real Estate Investment Trust shares trading on the New York Stock Exchange
Reuters
·
prieš 2 valandas
Wall St opens lower after hot CPI data fuels rate-hike bets
Profilis
GlobeImmune, Inc. is a clinical-stage public biopharmaceutical company headquartered in Louisville, Colorado, that develops therapeutic vaccines to treat cancer and infectious diseases. As of August 2014, the company had no marketed products. GlobeImmune’s therapeutic vaccines are developed on the company’s Tarmogen immunotherapy platform. Tarmogens are made from genetically modified yeast that express one or more disease-associated antigens. Tarmogens activate T cells to specifically target and eliminate diseased cells with the same target antigen.
The company has partnerships with Celgene and the National Cancer Institute for the development of cancer vaccines. Their collaboration with Gilead for the development of therapeutic vaccines for the treatment of hepatitis B was terminated in November 2016 after the product they were developing failed a clinical trial the year before.
With respect to financing in the absence of revenue, the company raised US$17,500,000 through a Series E Preferred Stock offering in January 2010.
As of August 2015, GlobeImmune had two therapeutic vaccines in clinical trials, GI-6207 and GI-6301, for the treatment of various cancers. Wikipedia
Apie „GlobeImmune Inc“
Generalinis direktorius-
Darbuotojai22
Įkurta1995-01-01
Pagrindinė būstinėLouisville, Koloradas, Jungtinės Valstijos
Sektorius-
Svetainėglobeimmune.com